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Abstract
Background Aims: Sepsis and related disorders, especially acute lung injury (ALI), are the
most challenging life‐threatening diseases in the hospital intensive care unit. Complex
pathophysiology, unbalanced immune condition, and high rate of mortality complicate the
treatment of sepsis. Recently, cell therapy has been introduced as a promising option to
recover the sepsis symptoms. The aim of this study was to investigate the therapeutic
potential of human unrestricted somatic stem cells (USSCs) isolated from human umbilical
cord blood in the mouse model of ALI. USSCs significantly enhanced the survival rate of
mice suffering from ALI and suppressed concentrations of proinflammatory mediators
TNF‐α, and interleukin (IL)‐6, and the level of anti‐inflammatory cytokine IL‐10. ALI mice
injected by USSCs showed notable reduction in lung and liver injury, pulmonary edema,
and hepatic enzymes, compared with the control group. These results determined the in
vivo immunomodulatory effect of USSCs for recovery of immune balance and reduction of
tissue injury in the mouse model of ALI. Therefore, USSCs can be a suitable therapeutic
approach to manage sepsis disease through the anti‐inflammatory potential.
K E YWORD S
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1 | INTRODUCTION
Sepsis is defined as systemic inflammation followed by an intensive
bacterial or fungal infection and is associated with a high rate of
mortality (Mayr, Yende, & Angus, 2014). Hyperactivation of innate and
acquired immune systems against pathogens leads to cytokine storm
and, ultimately, multiorgan injury (van der Poll & Opal, 2008). Lung
failure is the most frequent challenge related to sepsis and leads to
acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
Lipopolysaccharides (LPS), endotoxins derived from gram‐negative
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bacteria, are the most potent factor to induce ALI in humans and
animals. LPS induces production of different kind of cytokines, such as
TNF‐α, interleukin (IL)‐1b, IL‐6, IL‐10, and IL‐12 in both human and
murine monocytes, which may trigger extensive inflammatory re-
sponses (Rossol et al., 2011; H. M. Wang, Bodenstein, & Markstaller,
2008). Although new evidence suggests that the mortality rate of ALI/
ADRS has declined recently, it still remains about 26% in the USA
(Erickson, Martin, Davis, Matthay, & Eisner, 2009). The current
guidelines for the management of sepsis recommend procedures like
antibiotic therapy, fluid therapy, and administration of blood products in
the early stages of the disease (Rhodes et al., 2017). The current
standard treatment of sepsis will not be liable in the near future
because of factors like the advent of antibiotic‐resistant microbes; so, a
new therapeutic approach is required to overcome this challenge
(Grimaldi & Vincent, 2017). Cell therapy, as an alternative therapeutic
option with a live‐cell formulation, displays significant outcomes in
inflammatory diseases. Selection of suitable cell candidates for a
therapeutic approach is the most challenging issue in the cell‐based
therapy era. Recent studies have determined that mesenchymal stromal
cells (MSCs) can be efficient on sepsis and related disorders due to
immunomodulatory effects. In fact, MSCs can improve immune balance
in sepsis patients by regulation of immune cell function, which is very
significant in the management of inflammatory condition like ALI/ADRS
(Johnson, Soeder, & Dahlke, 2017). MSCs isolated from different types
of tissues, such as bone marrow (Krasnodembskaya et al., 2012),
adipose tissue (Elman, Li, Wang, Gimble, & Parekkadan, 2014), umbilical
cord (Li, Li, Liu, Tang, & Wei, 2012), and Wharton's jelly (Cóndor et al.,
2016), have been studied in the mouse model of sepsis. Administration
of MSCs results in modulation of cytokines, improvement of organ
injuries, and elevation of survival rate. On the other hand, noninvasive
isolation and access to appropriate cell count for infusion are the
concerns of stem cell therapy.
Human unrestricted somatic stem cell (USSC) is a nearly new cell
type isolated from umbilical cord blood for the first time in 2004 by
Kogler and colleagues. These cells are called pluripotent or MSCs
progenitor because of their higher proliferative activity and the wide
range of differentiation capacity. USSCs can expand up to 1015 cells
without deviation in normal karyotype and emersion of cell
senescence (Kögler et al., 2004). Significantly, differentiation of USSCs
to various cell types of all three germ layers is determined in both in
vitro and in vivo studies (Wernet, Trapp, Zweigerdt, Mann, &
Trompeter, 2010). A low immunogenic nature similar to MSCs is an
appropriate property of USSC, which paves the path for cell therapy
applications. The therapeutic effect of these cells has been investi-
gated in different preclinical studies that provided promising
consequences. Transplantation of USSCs to the myocardial infarction
(MI) animal model improves left ventricle function due to secretion of
trophic factors and regulation of cytokines (Rabald et al., 2008).
Intrahepatic injection of USSCs in the murine model of epidermolysis
bullosa is followed by cell migration to blistering sites and recovery of
injuries occurrs in response to secretion of type VII collagen (Liao
et al., 2015). Regulation of cellular immunity, as the more considerable
property of USSCs, is provided by secretion of different cytokines.
Mixed lymphocyte reaction test in the presence of USSCs has clarified
the immunomodulatory effect of these cells against different HLA
classes and gene polymorphisms (Ebrahimi et al., 2010). So, USSC may
be a valuable source for ALI cell therapy due to ease of availability,
noninvasive processing, significant proliferation potential, acceptable
immunomodulatory, and nonimmunogenic traits.
In the present study, we investigated the therapeutic potential of
USSCs in the mouse model of ALI to evaluate the immunomodulatory
effect of transplanted cells on the systemic inflammation induced by
LPS. Moreover, the tissue protective capacity of USSCs was assessed
on the lung and liver damage caused by widespread inflammatory
responses.
2 | MATERIALS AND METHODS
2.1 | Animal care
Male C57BL/6 mice (8–12 weeks old, weighing 22–30 g) were
purchased from the Tehran Laboratory Animal Center, Tehran, Iran.
All mice were housed in the animal facility at the Tehran University
Laboratory Animal Center according to the NIH animal care guide-
lines. All animal experimental procedures were approved by the
Animal Care Committee of the Tehran University of Medical Sciences.
2.2 | Isolation and expansion of USSCs
Collection of umbilical cord blood was performed after mothers' informed
consent according to the approved ethical guidelines of the Tehran
University of medical sciences. USSCs were isolated and cultured
according to Kogler et al. (2004)'s procedure with minor modifications.
Briefly, mononuclear cells were fractionated from cord blood first by
hydroxyethyl starch buffer (Sigma‐Aldrich, St. Louis, MI) followed by ficoll
(Panbiotech, Germany) density gradient. After the lysis of RBCs,
5–7×106 isolated cells were counted and cultured in T25 flasks with
the specific medium, including DMEM low glucose (Gibco‐BRL, Grand
Island, New York) supplemented with 30% FBS, dexamethasone 10−7M
(Sigma‐Aldrich), 2mM glutamine (Gibco), 100 U/ml streptomycin (Gibco),
and 100mg/ml penicillin (Gibco). Cell incubation was prepared at 37°C in
5% CO2. USSC colonies were appeared 5–10 days later and passaged
with 0.25% trypsin. The cells were expanded in the same medium
supplemented with 10% FBS without dexamethasone.
2.3 | Analysis of surface markers
To confirm the identity of cells, surface markers including CD105, CD90,
CD73, CD31, CD34, CD45, and HLA‐DR were analyzed by flow
cytometry (BD FACSCalibur, BD Biosciences, Qume Drive, San Jose).
2.4 | In vitro differentiation
To induce osteocyte differentiation, USSC cells were cultured in
specific medium containing DMEM (Gibco), 10% FBS (Gibco), 10mM
β‐glycerol phosphate (Sigma‐Aldrich), 10−7 M dexamethasone, and
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50 μg/ml ascorbic acid biphosphate (Sigma‐Aldrich) for 21 days.
Alizarin Red (Sigma‐Aldrich) staining was served to confirm calcium
deposits.
Adipocyte differentiation was determined by Oil Red O staining
followed by 21‐day culture of USSC in DMEM supplemented with
10% FBS, 250 nM dexamethasone, 60 nM insulin, 0.5 mM isobutyl‐
methylxanthine, 0.2 mM and indomethacin (all from Sigma‐Aldrich).
For detection of DLK‐1 via immunocytochemistry, the cultured
cells were washed and fixed by 4% (v/v) paraformaldehyde (Sigma‐
Aldrich) in PBS for 20min. After blocking with 10% goat serum for
1 hr, the cells were incubated with DLK‐1 primary antibody (Abcam).
The samples were washed three times with PBS followed by 1‐hr
incubation with a secondary antibody in room temperature. The nuclei
were stained by 4ʹ, 6‐diamidino‐2‐phenylindole (Sigma‐Aldrich).
2.5 | LPS‐induced sepsis and experimental design
LPS from Escherichia coli o55:25 (L2880; Sigma‐Aldrich) was liquefied
in phosphate buffer saline with 1mg/ml concentration. To induce
endotoxemia, the mice were injected intraperitoneally by 400 μg/
mouse dilution and randomly assigned in one of three groups: (a) LPS
group, (b) LPS+USSC group, and LPS+PBS group (n = 6 for each
group). A total of 1 × 106 USSC cells were washed and resuspended
in 200 μl PBS. Two hours after the LPS injection, the mice received
1 × 106 USSC cells or PBS by injection in the tail vein. The animals
were killed 24 hr after USSC or PBS treatment of cytokine
measurement, tissue histopathology, and biochemical analysis. For
survival study, three groups of mice (n = 8) were monitored every
12 hr for 7 days.
2.6 | Lung and liver histopathology
Lung and liver were harvested from each examined group 24 hr after
treatment. After fixation with 10% formalin (Merck, Germany), the
samples were embedded in paraffin and cut into sections with a
thickness of 5 μm. Hematoxylin and eosin‐stained samples were
analyzed by a veterinary pathologist to evaluate tissue injury and
inflammation.
2.7 | Wet‐dry analysis
Harvested lungs from all tested groups (n = 3) were placed into
microcentrifuge tubes and weighted. After overnight desiccating in a
85°C oven, the lungs were weighted again. The wet‐dry ratio was
assessed by dividing the weight of wet lung into the weight of dry ones.
2.8 | Measurements of serum cytokines
For detection of cytokines, mouse blood samples were obtained by
cardiac puncture and incubated in room temperature for 20min to
clot. After centrifugation at 400 g for 5 min, the serum was collected
and stored at −80 °C. The serum levels of IL‐6 (ab100712; Abcam,
UK), IL‐10 (M1000B; R&D systems) and TNF‐α (ab208348; Abcam,
UK) were measured by ELISA according to the manufacturer's
protocol. All samples were run in triplicate, and the absorbance of
each sample was measured by ELISA reader (ELx800TM, BioTek
Instruments, Italy) at 450 nm.
2.9 | Blood biochemical analysis
The serum levels of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were analyzed by (selectra ProM, ELITech
Group, France) according to the manufacturer's instruction.
2.10 | Statistical analysis
All data are expressed as the mean ± standard error of the mean.
Statistical analysis of data was accomplished by using the GraphPad
Prism 6 software. Differences between groups were evaluated with
one‐way analysis followed by Newman‐Keuls posttest. The survival
rate of mice was analyzed by the Caplan–Meier method, and group
compression was assessed via the Mantel–Cox log‐rank test. The
statistical significance for differences between values was accepted
at p < 0.05.
3 | RESULTS
3.1 | Characterization and immunophenotyping of
USSCs
Fourteen days after isolation, the adherent colon of USSCs was
observed, which appeared in single spindle shape morphology after
the first passage (Figure 1a,b). Analysis of immunophenotyping by
flow cytometry revealed that the cells were positive for CD90, CD73,
and CD105 but negative for CD45, CD34, CD31, and HLA‐DR
(Figure 1c). Osteogenic differentiation of the cells at passage 4 was
confirmed after 21 days culture in specific media followed by Alizarin
red staining (Figure 1d). Differentiation of USSCs to adipogenic
lineage after 21‐day cell culture in adipo‐induction medium was not
proved by Oil red staining (Figure 1e); therefore the cells were
immunostained by the DLK‐1 antibody as a specific marker for
characterization of USSCs (Figure 1f; Figure 2)
3.2 | USSCs treatment attenuates systemic
inflammatory responses
TNF‐α and IL‐6 are the main proinflammatory cytokines that play a
critical role in the progression of sepsis (Ulloa & Tracey, 2005). On the
other hand, the serum level of IL‐10 as an anti‐inflammatory cytokine
increase followed by LPS injection. Therefore, we studied the amount
of the above cytokines 24 hr after cell or saline treatment (Figure 3).
LPS notably enhanced the serum concentration of TNF‐α, IL‐6, and IL‐
10 in the reference time interval (p < 0.01, p < 0.001, p < 0.0001,
respectively). Although PBS treatment was not effective on the serum
levels of cytokines, the administration of USSCs significantly declined
the abundance of both pro‐ and anti‐inflammatory cytokines close to
BEHJANI ET AL. | 3
control counterparts (p < 0.01 for TNF‐α, IL‐6, and p < 0.001 for IL‐10).
These results suggest that USSCs can efficiently modulate systemic
immune responses induced by LPS.
3.3 | USSCs prevents severe lung and liver injury
Twenty‐four hours after LPS injection, severe hemorrhage, asso-
ciated with hemosiderin, fibrosis, and alveolar thickening, was
observed. Histological analysis of LPS‐induced liver tissue showed
severe necrosis of hepatocytes, and the central vein became dilated
and congested. Moreover, intensive infiltration of neutrophils
occurred in both lung and liver sections. Saline injection after LPS
intervention also displayed hepatocyte necrosis, lung edema, alveolar
fibrosis, and increase in inflammatory cells. Although USSC treatment
of ALI mice was associated with moderate injuries, the intensity of
fibrosis, pulmonary edema, and neutrophil infiltration was signifi-
cantly decreased, as well as a regenerative foci of hepatocytes in the
response of mild necrosis was detected in liver tissue (Figure 3).
3.4 | USSCs treatment enhances ALI survival rate
Administration of cells or PBS was performed 2 hour after injection
of LPS. The mice were followed up every 12‐hr for 7 days to evaluate
the survival rate of each group. The Caplan–Meir curve showed 25%
(2 of 8 mice surviving until 60 hr) after LPS intervention, whereas
USSCs treatment improved survival rate to 87.5% (7/8) compared
with the LPS group (p = 0.004). However, intravenous infusion of
saline did not significantly alter mortality compared with the
F IGURE 1 Characterization of isolated USSCs. (a) USSC colony appeared after 2 weeks of isolation and (b) USSCs with high confluency
(magnification 100×). (c) Immunophenotyping of USSCs showed that the cells are positive CD90, CD73, CD105, and negative for CD45, CD34, CD31,
and HLA‐DR markers. Differentiation pattern of USSC (d) to osteocyte that showed by Alizarin red staining and (e) to adipocyte lineage that not
proved by Oil red O staining (magnification 100×). (f) Immunocytochemistry of USSCs with DLK‐1 antibody (green), the nucleus of cells was stained
by DAPI (blue). DAPI: 4ʹ,6‐diamidino‐2‐phenylindole; USSC: unrestricted somatic stem cells [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Administration of USSCs balances the systemic inflammation caused by LPS. LPS intervention resulted in increasing
concentrations of (a) IL‐6 and (b) TNF‐α as the proinflammatory agents and (c) IL‐10 as a major anti‐inflammatory cytokine. Intravenous
injection of USSCs effectively reduces the serum level of above cytokines. n = 3 per group. ∗p < 0.05; ∗∗p < 0.01; and ∗∗∗p < 0.001 and
****p < 0.0001. LPS: lipopolysaccharides; USSCs: unrestricted somatic stem cells
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untreated group (3 of 8 mice remained with 37.5% survival rate) but
the comparison of this group with USSC group was statistically
considered (p = 0.017; Figure 4).
3.5 | USSCs treatment balance liver enzymes
Liver enzymes AST and ALT release in response to hepatocellular injury
and are considered liver dysfunction indicators. The serum amount of
AST and ALT was significantly increased in the mice model as a result of
LPS injection compared with the control group (p < 0.001 and p < 0.01,
respectively). Figure 5a,b represent that tail vein administration of
USSCs effectively declined the concentration of liver enzymes (ALT
106.3 ± 5.13 U/L, p <0.05 and AST 270.3 ± 8.35 U/L, p <0.05) in
comparison with the saline group (ALT 144 ± 8.14 U/L and AST
338 ± 13.6 U/L). Consequently, USSCs contributed to liver function
recovery by presenting this hepatic protective effect.
3.6 | USSCs treatment alleviates lung edema
The state of pulmonary edema, which was scored by wet/dry ratios of
lungs, was improved after 24‐hr injection of LPS (p < 0.0001). The
mice model that received USSCs showed a remarkable reduction in
wet/ dry weight ratio versus LPS and saline groups (p < 0.001 and
p < 0.01, respectively; Figure 5c).
4 | DISCUSSION
In this study, USSC was successfully isolated from umbilical cord
blood and characterized based on the pattern of CD markers,
osteocyte determination, no adipogenic differentiation capacity, and
DLK‐1 expression. These cells were used as a new cell therapy
approach in the ALI mouse model. The result of this study determine
that intravenous administration of USSC 2 hr after LPS‐endotoxemia
induction notably upgraded survival rate, clearly recovered the
systemic and pulmonary inflammatory responses, and improved the
histopathological state of liver and lung injury.
Sepsis is known as the systemic inflammatory response syndrome
(SIRS), which is characterized by cytokine release, severe tissue
injury, and ischemia‐reperfusion (Angus & van der Poll, 2013). Lungs
are the most susceptible organ and the origin of sepsis inflammatory
condition that finally appears as respiratory diseases like ALI and
ARDS (Hostiuc, Dermengiu, Ceausu, Rusu, & Curca, 2011). Bacterial
toxins, especially endotoxins, are certainly the most considerable
factor in the development of sepsis. LPS is the most important
component of the gram‐negative bacteria that triggers intense
inflammation in both human and animal models (Copeland, Warren,
Lowry, Calvano, & Remick, 2005; Ramachandran, 2014). Intraper-
itoneal injection of LPS in mice results in intensive secretion of
cytokines, alteration of respiratory function, induction of pulmonary
F IGURE 3 USSCs treatment rescue the lung and liver sever injury in mice model of ALI. In the LPS group, severe hemorrhage (star)
associated with hemosiderin (black arrow), neutrophil infiltration (green arrow), and fibrosis causing alveolar wall thickness (arrowhead) in the
lung biopsy and severe necrosis of hepatocytes (star), neutrophil infiltration (black) in the liver. USSC treatment reduced infiltration of
inflammatory cells (green arrow), lung fibrosis and hepatocyte necrosis (arrow). Magnifications: (a) and (g) ×100, (b) ×10, (d) ×20, (c), (e), (f), and
(h) are ×40, all inlets in the corner of (c), (e), and (f) are ×100. ALI: acute lung injury; LPS: lipopolysaccharides; USSC: unrestricted somatic stem
cells [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 4 The survival rate of LPS‐induced mice improved after
treatment of USSCs. Caplan–Meir curve showed the percentage of
surviving mice in LPS injected (n = 8), LPS+PBS infused (n = 8) and
USSCs treated group (n = 8). USSCs significantly improve the survival
rate of ALI‐suffering mice compared with the untreated group (87/
5% vs 25%; p = 0.004). ALI: acute lung injury; LPS:
lipopolysaccharides; PBS: phosphate‐buffered saline;
USSC: unrestricted somatic stem cells
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edema, and accumulation of inflammatory cell (Rojas, Woods, Mora,
Xu, & Brigham, 2005). Hence, we prepared the mouse model of ALI‐
related sepsis by administration of LPS to investigate the therapeutic
effects of USSC cells as a cell therapy candidate.
Recently, several preclinical studies reported the anti‐inflamma-
tory and immune regulatory effects of MSCs on different type of
sepsis animal models. Bone marrow and adipose tissue‐derived MSCs
served as the new therapeutic option in sepsis clinical trials (Wilson
et al., 2015; Zheng et al., 2014). Because cell‐based therapy may
efficiently manage sepsis‐related disorders, plenteous studies have
been performed to introduce a suitable cell source. Ease availability,
noninvasive isolation method, low immunogenicity, and high‐prolif-
erative potential are the main features that must be considered to
access desired consequences. Furthermore, for successful cellular
therapy in the sepsis era, it is necessary to modulate enhanced
inflammatory responses, decrease organ injuries, and decline mortal-
ity. MSC derived from different sources is studied as a cell therapy
candidate in sepsis and ALI animal models because of its remarkable
immunomodulatory and regenerative effects (Johnson et al., 2017).
Despite suitable characteristics of MSCs, some challenges remain
insoluble like low proliferation rate and precocious senescence. USSC
cells, which are derived from umbilical cord blood with high‐
proliferative potential and a wide range of differentiation capability,
share some MSC traits like low immunogenicity and immunomodula-
tory properties. Differentiation capacity of USSCs to various type of
cells with different embryonic origin is determined in both in vitro and
in vivo experiments. Regenerative and therapeutic quality of USSCs is
studied in several preclinical models including MI (Iwasaki et al., 2009;
Kim et al., 2005), bone healing (Handschel et al., 2010; Jäger et al.,
2007), and spinal cord injury (Schira et al., 2012). Cell‐based therapy
for the murine model of wound healing and epidermolysis bullosa was
also determined via secretion of type VII collagen by USSCs (Liao et al.,
2015). In the case of infectious diseases, there has been no report of
USSC treatment in preclinical experiments. Given the significant
possibility of immunomodulation and regeneration, USSC can be
introduced as a new cell‐based option for ALI and sepsis management.
LPS induction activates the TLR4‐related signaling pathways,
which finally results in increasing proinflammatory cytokines. On the
other side, the production of anti‐inflammatory cytokines like IL‐10
also occurs by LPS induction. The recovery of the balance between
pro‐ and anti‐mediators is the major purpose of sepsis management
(H. D. Wang, Lu, & Qi, 2009). IL‐6 and TNF‐α are two main
proinflammatory cytokines that enhance rapidly after LPS inocula-
tion (Rojas et al., 2005). In the present study, in spite of the intense
increase in the serum level of IL‐6 and TNF‐α after LPS injection,
USSC treatment effectively reverts the amount of this component
close to the normal state. Hence, USSC therapy, as a new option for
sepsis management, could mediate the remission of cytokine storm.
The controversial role of IL‐10 in the systemic inflammation is not
completely understood because of some adverse effects in septic patients
and different outcomes of animal models. In human sepsis, the elevated
concentration of IL‐10 is associated with a higher risk of infection
maintenance, organ injury, and death. IL‐10 is associated with the
development of sepsis in trauma patients (Giannoudis et al., 2000).
Moreover, prolongation of the expression of anti‐inflammatory cytokines
leads to the appearance of a critical state termed compensatory
F IGURE 5 USSCs alleviate high level of
hepatic enzymes and pulmonary edema
induced by LPS. (a,b) The serum levels of
liver biomarkers, aspartate
aminotransferase (AST), and alanine
aminotransferase (ALT) were evaluated in
each exanimated group. Cell treated mice
represent a lower dose of AST and ALT
compared with the LPS group (p < 0.05).
(c) Lung edema was measured by wet/dry
weight ratio. n = 3 per group. ∗p < 0.05;
∗∗p < 0.01; and ∗∗∗p < 0.001. LPS:
lipopolysaccharides; USSC: unrestricted
somatic stem cells [Color figure can be
viewed at wileyonlinelibrary.com]
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anti‐inflammatory response syndrome (CARS) and finally deactivation of
the immune system (Ward, Casserly, & Ayala, 2008). Therefore, IL‐10
needs to sustain in the rational enhanced level, which suppresses
inflammatory responses but does not trigger CARS. The enhancement of
IL‐10 level to approximately two folds observed after LPS intervention is
in the agreement with other reports (Hu et al., 2016; Li et al., 2012).
Administration of USSC could decline the rebellious amount of IL‐10, but
in the compression with the normal state, the serum level of IL‐10 was
still elevated. This event seems beneficial to support the balance of
immune system reactions in the inflammatory condition.
The experimental results determined that USSCs treatment improved
the survival of ALI‐suffering mice probably raised from the suppression of
inflammatory responses and regenerative effects. Lungs are the most
vulnerable organ in septic patients with a notably poor outcome. Lung
dysfunction symptoms reveal as the destruction of cellular connections,
increase in vascular permeability resulted in pulmonary edema, and
infiltration of inflammatory cells. Neutrophils extend the organ injuries by
secretion of some damaging substances like cytokines, granular enzymes,
reactive oxygen species, and the organization of neutrophil extracellular
traps (Fujishima, 2016). In this study, infusion of USSCs diminished the
intra‐alveolar infiltration of neutrophils and reduced lung edema and
fibrosis in comparison with LPS‐induced mice. Therefore, the cells may be
a useful approach in moderating severe lung damage arising from the
function of inflammatory cells.
Lung edema evaluated by wet/dry weighting arising from fluid
effusion was followed by endothelial cell barrier destruction. The
devastation of pulmonary endothelium barrier is frequently induced
by LPS challenge in ALI animal model (Feng et al., 2013). USSC cells
significantly declined the wet/dry ratio and consequently abnormal
pulmonary edema 24 hr after administration. The ultimate therapeu-
tic effect of USSC in pulmonary edema was notably along with MSCs‐
derived from the umbilical cord (Li et al., 2012) and MSCs‐educated
macrophages (Hu et al., 2016) that showed antiedema activity.
The liver is proposed as a critical organ in surviving patient
with sepsis and related disorders because of detoxification
functions. Liver damage is primed in the early stage of sepsis as
a result of endotoxin and cytokine release, which is associated
with some serological and histological change including severe
increase of hepatic enzymes, hepatocyte apoptosis, necrosis, and
neutrophil accumulation (Nesseler et al., 2012; Yan, Li, & Li, 2014).
USSCs diminished liver injury in ALI mice by the reduction of
hepatocyte necrosis, neutrophil infiltration, and vein dilation. On
the other side, the decrease in the serum level of AST and ALT as
the markers of hepatic damage may evidence the therapeutic
effect of the cells on the liver dysfunction.
According to the results of this study, the xenotransplantation
of USSC declined the mortality of LPS‐challenged mice plus the
effective recovery in cytokine releases and organ injuries. USSC
secretome, containing various growth factors like angiopoietin‐2,
hepatocyte‐derived growth factor (HDGF), transforming growth
factor‐β and macrophage migration inhibitory factor (Schira et al.,
2015), may have a crucial effect in the treatment of a different
aspect of sepsis disease. Furthermore, low immunogenicity, high
proliferation, and nontumorigenicity, which is reported in the case
of USSCs, are the main priorities in cell‐based therapy. Our findings
demonstrate the in vivo anti‐inflammatory effect of USSC cells that
may provide a path to use in human sepsis clinical trials.
In conclusion, we have investigated the therapeutic effect of
USSCs derived from umbilical cord blood on the progression of LPS‐
induced ALI in which treated mice showed significant improvement in
survival rate, reduction of systemic inflammatory responses, and
moderation of organ injury. This study may provide promising results
to introduce a notable cell source for the management of infectious
disease to control inflammation and preserve the balance of immune
responses via an immunomodulatory function.
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